Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,258,887 papers from all fields of science
Search
Sign In
Create Free Account
RIPK1 protein, human
Known as:
Receptor-Interacting Serine/Threonine Kinase 1
, receptor (TNFRSF)-interacting serine-threonine kinase 1, human
, RIP Protein Kinase
Expand
Receptor-interacting serine/threonine-protein kinase 1 (671 aa, ~76 kDa) is encoded by the human RIPK1 gene. This protein plays a role in signaling…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
26 relations
Apoptosis
Caspase Cascade Pathway
Ceramide Signaling Pathway PID
DR3 and DR4/5 Mediated Apoptosis Pathway
Expand
Broader (3)
Protein-Serine-Threonine Kinases
Receptor-Interacting Protein Serine-Threonine Kinase 1
Receptor-Interacting Protein Serine-Threonine Kinases
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Caspase-8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome.
T. Kang
,
Seung-Hoon Yang
,
Beáta Tóth
,
A. Kovalenko
,
D. Wallach
Immunity
2013
Corpus ID: 205417501
Highly Cited
2012
Highly Cited
2012
Reconstruction of f(T) gravity: Rip cosmology, finite-time future singularities, and thermodynamics
K. Bamba
,
R. Myrzakulov
,
S. Nojiri
,
S. Odintsov
2012
Corpus ID: 118609489
We demonstrate that there appear finite-time future singularities in $f(T)$ gravity with $T$ being the torsion scalar. We…
Expand
Highly Cited
2001
Highly Cited
2001
Drosophila immune deficiency (IMD) is a death domain protein that activates antibacterial defense and can promote apoptosis.
P. Georgel
,
S. Naitza
,
+7 authors
J. Hoffmann
Developmental Cell
2001
Corpus ID: 33526767
Highly Cited
2000
Highly Cited
2000
The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation.
Anne Devin
,
Amy Cook
,
Yong Lin
,
Yolanda Rodriguez
,
M. Kelliher
,
Zheng-Gang Liu
Immunity
2000
Corpus ID: 21458822
Highly Cited
1999
Highly Cited
1999
Multiple Signal Input and Output Domains of the 160-Kilodalton Nuclear Receptor Coactivator Proteins
Han Ma
,
H. Hong
,
+5 authors
M. Stallcup
Molecular and Cellular Biology
1999
Corpus ID: 26029245
ABSTRACT Members of the 160-kDa nuclear receptor coactivator family (p160 coactivators) bind to the conserved AF-2 activation…
Expand
Highly Cited
1999
Highly Cited
1999
Phosphorylation of Serine‐880 in GluR2 by Protein Kinase C Prevents Its C Terminus from Binding with Glutamate Receptor‐Interacting Protein
S. Matsuda
,
S. Mikawa
,
H. Hirai
Journal of Neurochemistry
1999
Corpus ID: 39402443
Abstract : Phosphorylation of the glutamate receptor is an important mechanism of synaptic plasticity. Here, we show that the C…
Expand
Highly Cited
1998
Highly Cited
1998
The death domain kinase RIP mediates the TNF-induced NF-kappaB signal.
M. Kelliher
,
S. Grimm
,
Y. Ishida
,
F. Kuo
,
B. Stanger
,
P. Leder
Immunity
1998
Corpus ID: 41596942
The death domain serine/threonine kinase RIP interacts with the death receptors Fas and tumor necrosis receptor 1 (TNFR1). In…
Expand
Highly Cited
1998
Highly Cited
1998
Novel Anchorage of GluR2/3 to the Postsynaptic Density by the AMPA Receptor–Binding Protein ABP
S. Srivastava
,
P. Osten
,
+9 authors
E. Ziff
Neuron
1998
Corpus ID: 14448034
Highly Cited
1997
Highly Cited
1997
CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP.
Manzoor Ahmad
,
S. Srinivasula
,
+4 authors
E. Alnemri
Cancer Research
1997
Corpus ID: 18574396
FADD/MORT1 is a death domain (DD)-containing adaptor/signaling molecule that interacts with the intracellular DD of FAS/APO-I…
Expand
Review
1997
Review
1997
Exploring and explaining epigenetic effects.
Steven Henikoff
,
M. Matzke
Trends in Genetics
1997
Corpus ID: 33644889
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE